You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1054 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib – For the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma, in combination with nivolumab, according to clinical criteria
New Drug Funding Program
    Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Nov 2024

Pages